EUVIMEDEUVIMED entdecken
Delphi-Studie

Pulmonary sarcoidosis clinical trial end-points: a Delphi study

Robert P Baughman, Jan C Grutters iD, Elyse E Lower, Ying Zhou, Marlies Wijsenbeek, Athol U Wells, Marcel Veltkamp, Dominique Valeyre, Paolo Spagnolo, Michelle Sharp, Jacobo Sellares, Ogugua N Obi iD und 6 weitere

European Respiratory Journal · 2025

DOI: 10.1183/13993003.00943-2025 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Robert P Baughman und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Cincinnati, Cincinnati, OH, USA baughmrp@ucmail.uc.edu. Hauptthemen laut MEDLINE: Sarcoidosis, Pulmonary, Adrenal Cortex Hormones, Clinical Trials as Topic, Endpoint Determination. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Corticosteroids, the most commonly prescribed treatment for sarcoidosis, are associated with significant toxicity, especially with long-term usage. New intervention trials designed to reduce or eliminate corticosteroids require pertinent and precise clinical trial end-points. However, consensus is lacking. The aim of the current study is to develop consensus for trial end-points in pulmonary sarcoidosis.

Methods

A Delphi survey was developed by an Expert Panel of 30 sarcoidosis investigators. For Round 1, the panel created 97 statements regarding potential end-points for a clinical trial of symptomatic pulmonary corticosteroid-treated sarcoidosis patients. After anonymous voting in Round 2, the 97 statements were refined by all Stakeholders, including the Expert Panel and an additional 70 individuals interested in sarcoidosis therapies.

Results

After Round 2, the Expert Panel achieved consensus for combination end-points on 38 statements across six domains that supported the following end-points: prednisone reduction by 50% or discontinuation, 10% predicted or greater improvement in forced vital capacity % predicted, forced expiratory volume in 1 s % predicted and diffusing capacity of the lung for carbon monoxide % predicted, and improvement in the King's Sarcoidosis Questionnaire Lung and General Health domains. Additionally, the majority of Stakeholders agreed to all statements which reached consensus by the Expert Panel.

Conclusions

Utilising the Delphi technique, international sarcoidosis experts successfully achieved consensus for 38 specific clinical trial end-points which can be utilised in the development of novel steroid-sparing and eliminating therapies for pulmonary sarcoidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoidosis, PulmonaryAdrenal Cortex HormonesClinical Trials as TopicEndpoint DeterminationHumansDelphi TechniqueConsensusSurveys and QuestionnairesForced Expiratory VolumePrednisoneVital Capacity

Substanzen

Adrenal Cortex HormonesPrednisone

Autor:innen und Institutionen

  • Department of Medicine, University of Cincinnati, Cincinnati, OH, USA baughmrp@ucmail.uc.edu.
  • ILD Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.
  • Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • Center of Excellence for Interstitial Lung Diseases and Sarcoidoses, Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Jan C Grutters, Ogugua N Obi, Francesco Bonella

Zitieren

APA

Baughman, R. P., Grutters, J. C., Lower, E. E., Zhou, Y., Wijsenbeek, M., Wells, A. U., Veltkamp, M., Valeyre, D., Spagnolo, P., Sharp, M., Sellares, J., Obi, O. N., Nunes, H., Judson, M. A., Culver, D. A., Bonella, F., Azuma, A., & Korenromp, I. H. E. (2025). Pulmonary sarcoidosis clinical trial end-points: a Delphi study. European Respiratory Journal. https://doi.org/10.1183/13993003.00943-2025

Vancouver

Baughman RP, Grutters JC, Lower EE, Zhou Y, Wijsenbeek M, Wells AU, et al. Pulmonary sarcoidosis clinical trial end-points: a Delphi study. European Respiratory Journal. 2025. doi:10.1183/13993003.00943-2025

BibTeX
@article{Baughman2025,
  author = {Baughman, Robert P and Grutters, Jan C and Lower, Elyse E and Zhou, Ying and Wijsenbeek, Marlies and Wells, Athol U and Veltkamp, Marcel and Valeyre, Dominique and Spagnolo, Paolo and Sharp, Michelle and Sellares, Jacobo and Obi, Ogugua N and Nunes, Hilario and Judson, Marc A and Culver, Daniel A and Bonella, Francesco and Azuma, Arata and Korenromp, Ingrid H E},
  title = {Pulmonary sarcoidosis clinical trial end-points: a Delphi study},
  journal = {European Respiratory Journal},
  year = {2025},
  doi = {10.1183/13993003.00943-2025}
}
Kostenlos starten →